COR Cencora, Inc.
Wholesale-Drugs, Proprietaries & Druggists' Sundries · NYSE · SEC CIK 1140859 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.1%
TTM net income YoY38.3%
TTM EPS YoY38.3%
Revenue 3-yr CAGR9.4%
Net income 3-yr CAGR15.8%
Margins
Gross margin4.0%
Operating margin0.9%
Net margin0.8%
FCF margin1.2%
EBITDA margin1.2%
Returns
ROE104.3%
ROA3.3%
ROIC (approx.)22.3%
Asset turnover4.22x
Leverage & solvency
Liabilities / assets96.1%
Debt / equity3.84x
Current ratio0.93x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.84x
Accruals ratio-2.8%
Payout ratio17.8%
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-09-30 | FY20242024-09-30 |
|---|---|---|
| Income statement | ||
| Revenue | $321.33B | $293.96B |
| Cost of revenue | $309.85B | $284.05B |
| Gross profit | $11.48B | $9.91B |
| SG&A expense | $6.49B | $5.66B |
| Operating income | $2.63B | $2.18B |
| Pretax income | $2.26B | $2.00B |
| Income tax | $690.52M | $484.70M |
| Net income | $1.55B | $1.51B |
| EBITDA | $3.68B | $3.27B |
| EPS (basic) | 8.02 | 7.60 |
| EPS (diluted) | 7.96 | 7.53 |
| Dividends declared per share | 2.20 | 2.04 |
| Weighted avg. shares (diluted) | 195.21M | 200.28M |
| Balance sheet | ||
| Cash & equivalents | $4.36B | $3.13B |
| Receivables | $25.23B | $23.87B |
| Inventory | $20.49B | $19.00B |
| Current assets | $52.24B | $47.72B |
| PP&E, net | $2.54B | $2.18B |
| Goodwill | $13.68B | $9.32B |
| Intangibles | $3.77B | $4.00B |
| Total assets | $76.59B | $67.10B |
| Current liabilities | $57.82B | $54.28B |
| Short-term debt | $117.78M | $576.33M |
| Long-term debt | $7.54B | $3.81B |
| Total debt | $7.66B | $4.39B |
| Total liabilities | $74.84B | $66.31B |
| Shareholders' equity | $1.51B | $645.94M |
| Net debt | $3.30B | $1.26B |
| Shares outstanding | 193.94M | 194.94M |
| Cash flow statement | ||
| Operating cash flow | $3.88B | $3.48B |
| Capital expenditure | $667.98M | $487.17M |
| Free cash flow | $3.21B | $3.00B |
| Investing cash flow | -$4.98B | -$618.10M |
| Financing cash flow | $2.25B | -$2.33B |
| Depreciation & amortization | $1.05B | $1.09B |
| Stock-based compensation | $147.96M | $148.00M |
| Dividends paid | $437.08M | $416.17M |
| Share buybacks | $435.47M | $1.49B |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.